Pharmacopoeial Standards | News
New releases, new batches and discontinued standards from the Chinese Pharmacopoeia
Updated October 2026
Our catalog of Chinese Pharmacopoeia (Ch.P.) reference standards has been updated and now includes new products, new batches, and several discontinued items.
Complete product details for the new products are being finalized, but all new items are already available to order. Please contact our customer service team for assistance or to place an order.
New BP CRS released to support 2027 monographs
Important news for our pharmaceutical customers: the British Pharmacopoeia have announced the release of the following new BP chemical reference substances (BPCRS) to support new and updated finished product monographs within the 2027 edition of the BP.
These new BPCRS will support the evaluation of quality for several new generic drugs by our customers, ensuring people worldwide obtain the safe and effective medicines they need. They can help facilitate the manufacture of drugs used to treat a range of diseases including Parkinson’s, hypertension and inflammatory disorders.
The BP portfolio of legally enforceable written standards (monographs) and highly characterised physical standards (BPCRS) continues to grow to support the fight against global diseases.
All new BPCRS have again been released ahead of the BP 2027 coming into force on the 1 January 2027, in order to enable users to ensure they can comply with the BP monographs from day one.
Download our flyer—clickable codes will take you directly to each product in our shop. Contact us at info@labmix24.com or +49 2852 96064 00 with your questions or to order!
New releases, new batches and discontinued standards from the Chinese Pharmacopoeia
Updated September 2026
A number of Chinese Pharmacopoeia reference standards have been newly released, replaced with a new batch, or discontinued. While some product details are still pending, the new items are already available for order. If you're looking for a specific standard from these lists and can't find the current version in our shop, please don't hesitate to contact us directly to place your order.
New BP CRS released to support 2026 monographs
October 2025
The British Pharmacopoeia continues to develop high quality standards for medicines to treat the world’s major diseases. The BP team recently announced the addition of twelve new reference standards to the BPCRS catalogue. These will support new monographs included in the new 2026 edition of the British Pharmacopoeia. We have these now available to order in our shop—just click on the item numbers in the document below.
Please be advised, products BP-1319 and BP-1258 are expected for sales release by 30 October 2025. Don’t hesitate to contact us with your pre-order!
New releases, new batches and discontinued standards from the Chinese Pharmacopoeia
October 2025
A number of Chinese Pharmacopoeia reference standards have been newly released, replaced with a new batch, or discontinued. While some product details are still pending, the new items are already available for order. If you're looking for a specific standard from these lists and can't find the current version in our shop, please don't hesitate to contact us directly to place your order.
New Primary Standards to support BP 2025 monographs
November 2024
The British Pharmacopoeia has released 11 new, high-quality BP primary standards to help assure the quality of medicines for patients globally, across a range of therapeutic classes.
Cardiovascular events, including heart attacks and strokes, remain a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO) in June 2021, cardiovascular events account for an estimated 17.9 million deaths annually, representing 31% of all global deaths.
The use of medications like clopidogrel and doxazosin plays a significant role in reducing and preventing these events. Clopidogrel, an antiplatelet agent, prevents blood clots by inhibiting platelet aggregation, thereby reducing the risk of heart attacks and strokes, especially in patients with a history of cardiovascular disease. Doxazosin, an alpha-blocker, helps manage hypertension, a major risk factor for cardiovascular events, by relaxing blood vessels and improving blood flow. Together, these medications contribute to better cardiovascular health and lower the incidence of severe cardiovascular complications.
To view a standard directly in our shop, click on the item numbers in the downloadable document below.
New BP reference standards
November 2023
BP has just released 14 new, high-quality BP primary standards to help assure the quality of medicines for patients globally, across a range of therapeutic classes. To view a standard directly in our shop, click on the item numbers in the document below.